文献速递临床试验与 GCP

6毫米与10毫米直径全覆膜自膨式金属支架治疗不可切除恶性远端胆管狭窄(COSMIC UNISON):多中心随机对照试验研究方案

6-mm vs 10-mm diameter fully covered self-expandable metal stents in patients with unresectable malignant distal bile duct stricture (COSMIC UNISON): study protocol for a multicenter, randomized controlled trial.
PubMed 文献 · Trials · 2025-02-18

COSMIC UNISON是一项多中心、开放标签、随机对照非劣效性试验,计划在日本23个中心纳入250例不可切除恶性远端胆管狭窄患者,随机接受6毫米或10毫米全覆膜自膨式金属支架(FCSEMS)置入,每组125例。主要终点为支架通畅时间(TRBO),观察期24个月,旨在评估6毫米FCSEMS的疗效与安全性。

要点

  • 6毫米与10毫米FCSEMS头对头比较,主要终点为支架通畅时间(TRBO)。
  • 计划纳入250例,每组125例,日本23个中心,观察期24个月。
  • 次要终点包括非RBO事件发生率、总生存期、RBO原因及症状性支架移位。

核心结论

  • COSMIC UNISON研究预期为6毫米与10毫米FCSEMS的疗效和安全性提供证据,以指导6毫米FCSEMS用于不可切除恶性远端胆管狭窄的治疗。

研究设计与样本

  • 多中心、开放标签、随机对照、非劣效性试验(COSMIC UNISON),目标纳入250例患者,分配至日本23个中心,每组125例。
  • 患者在接受ERCP时置入6毫米FCSEMS或标准10毫米FCSEMS。
  • 观察期24个月,患者自2024年3月15日入组,评估至RBO发生日或研究结束(2029年3月31日)。

主要发现

  • 主要终点为支架通畅时间(TRBO),RBO定义为肝酶异常与支架上游胆总管及肝内胆管扩张并存。
  • 次要终点为非RBO事件的发生率及3、6、12个月时的发生率、总生存期、RBO原因和症状性支架移位。
  • 内镜操作相关不良事件按美国内镜学会Lexicon分类,其他不良事件按不良事件通用术语标准第5.0版日文译版分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unresectable malignant bile duct stricture (often caused by unresectable pancreatic cancer and cholangiocarcinoma) can be drained via insertion of self-expandable metal stents (SEMS) during endoscopic retrograde cholangiopancreatography (ERCP). Because recurrent biliary obstruction (RBO) and complications following stent insertion can delay chemotherapy and other treatments, a longer time to RBO (TRBO) is desirable. Although a longer TRBO has been reported among patients who undergo insertion with larger diameter SEMS, patients who undergo insertion with smaller diameter fully covered SEMS (FCSEMS) may have a lower incidence of complications than those with larger diameter FCSEMS. The aim of this study is to determine the TRBO and incidence of complications with 6-mm FCSEMS vs 10-mm FCSEMS in patients with unresectable malignant distal bile duct stricture. METHODS: In this multicenter, open-label, randomized controlled, non-inferiority trial (COSMIC UNISON), a target of 250 patients over 23 locations in Japan will receive either the 6-mm FCSEM or the standard 10-mm FCSEM during ERCP, with 125 patients in each group. The observation period will be 24 months, and patients will be enrolled from 15 March 2024 and assessed until the date of RBO or the study end (31 March 2029). The primary endpoint is TRBO, with RBO defined as the coexistence of abnormal liver enzyme values and dilation of the common bile duct and intrahepatic bile duct upstream of the stent. The secondary endpoints are the incidence and rates (at 3, 6, and 12 months) of non-RBO events, overall survival, cause of RBO, and symptomatic stent deviation. Adverse events from endoscopic procedures will be classified by the Lexicon Classification from the American Society of Endoscopy, and all other adverse events will be classified per the Japanese translation of the Common Terminology Criteria for Adverse Events version 5.0. DISCUSSION: The COSMIC UNISON study is anticipated to provide evidence regarding the efficacy and safety of 6-mm vs 10-mm FCSEMS to inform the use of 6-mm FCSEMS for the treatment of unresectable malignant distal bile duct stricture. TRIAL REGISTRATION: Japan Registry of Clinical Trials identifier: jRCT1042230170. Prospectively registered on 15 March 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yamada R, Tanaka T, Shimada Y, et al. 6-mm vs 10-mm diameter fully covered self-expandable metal stents in patients with unresectable malignant distal bile duct stricture (COSMIC UNISON): study protocol for a multicenter, randomized controlled trial. Trials. 2025. PMID: 39966935. doi:10.1186/s13063-025-08771-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。